Rua Bioscience Limited — Director's Dealing 2021

Apr 8, 2021

==> picture [89 x 27] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

==> picture [456 x 591] intentionally omitted <==

----- Start of picture text -----

To NZX Limited; and
Name of listed issuer: Rua Bioscience Limited ( Rua )
Date this disclosure made: 8-Apr-21
Date of last disclosure: 31-Mar-21
Director or senior manager giving disclosure
Full name(s): Manu Caddie
Name of listed issuer: Rua Biosicence Limited
Name of related body corporate (if applicable):
Kaihautu - Head of Innovation and
Position held in listed issuer:
Regulation of Rua
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: Ordinary shares in Rua
Manu is a director and 50%
shareholder of New Zealand
Nutraceuticals Limited ( NZNL ). NZNL is
a limited partner of Hikurangi Bioactives
Limited Partnership ( HBLP ) with a 40%
economic interest in HBLP. HBLP is the
Nature of the affected relevant interest(s):
registered holder and beneficial owner
of 23,015,258 (before the transaction)
and 22,578,706 (after the transaction)
ordinary shares in Rua.
For that relevant interest-
Number held in class before acquisition or disposal: 9,206,103
Number held in class after acquisition or disposal: 9.031,482
Current registered holder(s): HBLP
Registered holder(s) once transfers are registered: HBLP
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying financial
products (if any): N/A
A statement as to whether the derivative is cash settled or physically settled: N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative(if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the underlying
financial products: N/A
For that derivative,-
Parties to the derivative: N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant
interest in the derivative: N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 4
----- End of picture text -----

Details of transactions requiring disclosure-

Date of transaction:		(a) 31 March 2021 (b) 1 April 2021 (c) 6 April 2021 (d) 7 April 2021
Nature oftransaction:		On market sale
Name ofany otherparty orparties to the transaction(if known):		Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:		(a) NZ$12,847.12 being 40% of proceeds of HBLP's sale of 76,471 shares for $32,117.82 (before fees) (b) NZ$21,903.10 being 40% of proceeds of HBLP's sale of 130,000 shares for $54,757.75 (before fees) (c) NZ$28,373.78 being 40% of proceeds of HBLP's sale of 171,119 shares for $70,934.47 (before fees) (d) NZ$9669.76 being 40% of proceeds of HBLP's sale of 58,962 shares for $24,174.42 (before fees)
Numberof financialproducts towhichthe transaction related:		(a) 30,588 (being 40% of 76,471) (b) 52,000 (being 40% of 130,000) (c) 68,447 (being 40% of 171,119) (d)23,584(being40% of58,962)
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevantinterestswere acquired ordisposed ofduring a closed period:		No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed duringthe closedperiod:		N/A
Date of the prior written clearance(if any):		N/A
Summary of other relevant interests after acquisition or disposal: Class ofquotedfinancialproducts: Nature of relevantinterest: For that relevant interest,- Number heldinclass: Currentregisteredholder(s): For a derivative relevant interest,- Type ofderivative: Details of derivative,-
		Options that are convertible to ordinary shares in Rua under Rua's employee share optionplan
		Entitlement to become legal and beneficial owner subject to the meeting of vesting and other terms and conditions under Rua's employee share optionplan
		55,000 options potentially convertible to283,072ordinary shares
		N/A
		N/A
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):		N/A
A statement as to whether the derivative is cash settled or physically settled:		N/A
Maturity date of the derivative (if any):		N/A
Expiry date of the derivative (if any):		N/A
The price's specified terms (if any):		N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financialproducts:		N/A
For that derivative relevant interest,-		N/A
Parties to the derivative:		N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		N/A

Certification

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of director or officer: Date of signature: 8/04/21 or Signature of person authorised to sign on behalf of director or officer: Date of signature: Name and title of authorised person:

==> picture [455 x 536] intentionally omitted <==